我国成年HIV感染者/艾滋病病人抗逆转录病毒治疗研究进展

覃丽泰; 邢辉; 陈怡; 谢艺红; 阮玉华; 冯毅

doi:10.19837/j.cnki.ahyf.2024.06.011

PDF(842 KB)

安徽预防医学杂志 ›› 2024, Vol. 30 ›› Issue (6) : 479-483. DOI: 10.19837/j.cnki.ahyf.2024.06.011

综述

我国成年HIV感染者/艾滋病病人抗逆转录病毒治疗研究进展

覃丽泰^1,2, 邢辉², 陈怡³, 谢艺红¹, 阮玉华², 冯毅²

作者信息 +

Research progress on antiretroviral therapy for adult HIV/AIDS patients in China

QIN Litai^1,2, XING Hui ², CHEN Yi ³, XIE Yihong¹, RUAN Yuhua ², FENG Yi ²

Author information +

文章历史 +

摘要

抗逆转录病毒治疗(ART)能抑制HIV感染者/AIDS病病人HIV/AIDS病毒载量、降低死亡和二代传播风险,而停药和依从性降低影响ART效果。我国艾滋病防治策略取得了一定成效,但仍然面临脱失和耐药的问题。本文对我国成年HIV/AIDS ART研究进行文献综述。

Abstract

Antiretroviral therapy (ART) can suppress HIV/AIDS patients viral load,reduce the risk of death and secondary transmission,while discontinuation and reduced compliance can affect the effectiveness of ART.China's AIDS prevention and control strategy has achieved a certain effect,but it still faces the problem of deactivation and drug resistance.This article provides the literature review on adult HIV/AIDS patients ART research in China.

导出引用

覃丽泰, 邢辉, 陈怡, 谢艺红, 阮玉华, 冯毅. 我国成年HIV感染者/艾滋病病人抗逆转录病毒治疗研究进展[J]. 安徽预防医学杂志. 2024, 30(6): 479-483 https://doi.org/10.19837/j.cnki.ahyf.2024.06.011

QIN Litai, XING Hui , CHEN Yi , XIE Yihong, RUAN Yuhua , FENG Yi. Research progress on antiretroviral therapy for adult HIV/AIDS patients in China[J]. Anhui Journal of Preventive Medicine. 2024, 30(6): 479-483 https://doi.org/10.19837/j.cnki.ahyf.2024.06.011

中图分类号： R512.91

参考文献

[1] 中国疾病预防控制中心性病艾滋病预防控制中心.国家免费艾滋病抗病毒药物治疗手册 [M].4版.北京:人民卫生出版社,2016:3.
[2] Zhou C,Zhang W,Lu RR,et al.Benefits of early and immediate initiation of antiretroviral therapy among HIV patients in Chongqing,China[J].Biomed Environ Sci,2020,33(4):282-285.
[3] 国务院办公厅.国务院办公厅关于印发中国遏制与防治艾滋病“十三五”行动计划的通知.[EB/OL].(2017-02-06) [2023-07-08].https://ncaids.chinacdc.cn/jb/fzdt/mtbd/201702/t20170206_137874.htm.
[4] 吴欣锐,窦倩如,鲍宇刚,等.经性途径传播的HIV感染者性行为特征及对二代传播率的影响[J].中南大学学报(医学版),2016,41(7):715-720.
[5] Eisinger RW,Dieffenbach CW,Fauci AS.HIV viral load and transmissibility of HIV infection [J].JAMA,2019,321(5):451-452.
[6] 中国疾病预防控制中心性病艾滋病预防控制中心.2023年12月全国艾滋病性病疫情[J].中国艾滋病性病,2024,30(3):225.
[7] Zhao Y,Wei L,Dou Z,et al.Changing mortality and patterns of death causes in HIV infected patients - China,2013-2022[J].China CDC Wkly,2023,5(48):1073-1078.
[8] Jia J,Zhu Q,Deng L,et al.Treatment outcomes of HIV patients with hepatitis B and C virus co-infections in Southwest China:an observational cohort study[J].Infect Dis Poverty,2022,11(1):7.
[9] 邱月锋,吴守丽,夏品苍,等.福建省2004—2020年成人艾滋病抗病毒治疗患者生存情况及影响因素分析[J].中国艾滋病性病,2022,28(1):92-96.
[10] 付丽茹,肖民扬,贾曼红,等.云南省1989—2021年报告HIV/AIDS生存时间及影响因素分析[J].中华流行病学杂志,2023,44(6):960-965.
[11] Zhu Z,Xu Y,Wu S,et al.Survival and risk factors associated with mortality in people living with HIV from 2005 to 2018 in Nanjing,China[J].Front Public Health,2022,10:989127.
[12] 蔺茂文,裴迎新,陈清峰,等.湖北省荆州市1996—2021年HIV/AIDS病死率及其影响因素回顾性队列研究[J].中华流行病学杂志,2023,44(9):1369-1375.
[13] 车双双,王鑫,黄玉玲,等.2010—2019年南充市艾滋病抗病毒治疗患者死亡情况及相关因素分析[J].预防医学情报杂志,2021,37(12):1686-1692.
[14] 覃丽泰,黄精华,陈欢欢,等.广西柳州市HIV感染者早期及时治疗和初始用药方案对抗病毒治疗死亡及脱失的影响[J].中国热带医学,2024,24(2):126-131.
[15] Yin H,Ye R,Yang Y,et al.Longitudinal impact of compliance with routine CD4 monitoring on all cause deaths among treated people with HIV in China[J].Biosci Trends,2022,16(6):434-443.
[16] Zhu J,Yousuf MA,Yang W,et al.Mortality and attrition rates within the first year of antiretroviral therapy initiation among people living with HIV in Guangxi,China:an observational cohort study[J].Biomed Res Int,2021,2021:6657112.
[17] Yang Y,Li Y,Zhang X,et al.Effect of antiretroviral therapy initiation time and baseline CD4⁺ cell counts on AIDS-related mortality among former plasma donors in China:a 21-year retrospective cohort study[J].Glob Health Action,2021,14(1):1963527.
[18] Tang Z,Pan SW,Ruan Y,et al.Effects of high CD4 cell counts on death and attrition among HIV patients receiving antiretroviral treatment:an observational cohort study[J].Sci Rep,2017,7(1):3129.
[19] Zhao Y,Wu Z,McGoogan JM,et al.Immediate antiretroviral therapy decreases mortality among patients with high CD4 counts in China:a nationwide,retrospective cohort study[J].Clin Infect Dis,2018,66(5):727-734.
[20] Zhu J,Yang W,Feng Y,et al.Treatment effects of the differential first-line antiretroviral regimens among HIV/HBV coinfected patients in southwest China:an observational study[J].Sci Rep,2019,9(1):1006.
[21] 冯玉婷,许玉军,朱考考,等.海南省艾滋病抗病毒治疗脱失情况及影响因素分析[J].中国热带医学,2024,24(3):304-308.
[22] 曾亚莉,王菊,何丽,等.2005—2019年凉山州4县艾滋病抗病毒治疗脱失情况及其影响因素[J].中国公共卫生,2022,38(10):1334-1339.
[23] Ma J,Jin Y,Jiao K,et al.Antiretroviral treatment interruption and resumption within 16 weeks among HIV-positive adults in Jinan,China:a retrospective cohort study[J].Front Public Health,2023,11:1137132.
[24] Xie J,Gu J,Chen X,et al.Baseline and process factors of anti-retroviral therapy that predict loss to follow-up among people living with HIV/AIDS in China:a retrospective cohort study[J].AIDS Behav,2022,26(4):1126-1137.
[25] Telayneh AT,Tesfa M,Woyraw W,et al.Time to lost to follow-up and its predictors among adult patients receiving antiretroviral therapy retrospective follow-up studyAmhara Northwest Ethiopia[J].Sci Rep,2022,12(1):2916.
[26] Wekesa P,McLigeyo A,Owuor K,et al.Survival probability and factors associated with time to loss to follow-up and mortality among patients on antiretroviral treatment in central Kenya[J].BMC Infect Dis,2022,22(1):522.
[27] Zhao Y,Wu Z,McGoogan JM,et al.Nationwide cohort study of antiretroviral therapy timing:treatment dropout and virological failure in China,2011-2015[J].Clin Infect Dis,2019,68(1):43-50.
[28] Huang YC,Sun HY,Chuang YC,et al.Short-term outcomes of rapid initiation of antiretroviral therapy among HIV-positive patients:real-world experience from a single-centre retrospective cohort in Taiwan[J].BMJ Open,2019,9(9):e033246.
[29] Lilian RR,Rees K,McIntyre JA,et al.Same-day antiretroviral therapy initiation for HIV-infected adults in South Africa:analysis of routine data[J].PLoS One,2020,15(1):e0227572.
[30] 楼金成,王林,杨根,等.云南省人类免疫缺陷病毒感染者抗反转录病毒治疗期间脱失找回再入组情况及其影响因素的分析[J].中华传染病杂志,2022,40(2):79-83.
[31] 张超,付钰淋,李华,等.陕西省HIV/AIDS患者接受抗病毒治疗后病毒载量结果及其影响因素分析[J].实用预防医学,2019,26(4):397-399.
[32] 郭萌,周康平,蔡昆,等.2018—2020年湖北省新治疗HIV感染者病毒载量水平及影响因素研究[J].华南预防医学,2022,48(1):115-118.
[33] 马艳玲,楼金成,劳云飞,等.云南省实现艾滋病防治 “3个90%” 策略与成效[J].中国艾滋病性病,2022,28(8):884-887.
[34] 冯疆涛,李虎,许铭玉,等.阿克苏地区3 034例HIV/AIDS患者抗病毒治疗后病毒载量及影响因素分析[J].华南预防医学,2023,49(2):195-197+201.
[35] 黄卓君,郭颜艳,张晓敏,等.滁州市2018年HIV感染者和病人抗病毒治疗效果分析[J].安徽预防医学杂志,2021,27(6):479-482.
[36] Dorward J,Sookrajh Y,Gate K,et al.HIV treatment outcomes among people with initiation CD4 counts >500cells/μL after implementation of Treat All in South African public clinics:a retrospective cohort study[J].J Int AIDS Soc,2020,23(4):e25479.
[37] 刘磊,肖林,汤杰,等.四川省越西县和昭觉县HIV抗病毒治疗停药患者耐药调查[J].中国热带医学,2020,20(5):402-408.
[38] 陈宏利,周业胜,郝静静,等.抗病毒治疗前耐药对HIV感染者治疗3年后病毒学应答的影响[J].中华流行病学杂志,2022,43(11):1778-1783.
[39] 郑艳,陈橙,王志勇,等.HIV感染者和艾滋病病人服药依从性的影响因素分析[J].安徽预防医学杂志,2021,27(2):100-105.
[40] 史宏博,谭诗文,叶泽豪,等.2017—2022年浙江省宁波市艾滋病病毒感染者高传播风险发生率队列研究[J/OL].疾病监测,1-7[2024-08-05].http://kns.cnki.net/kcms/detail/11.2928.R.20240703.1700.002.html.
[41] Zuo Z,Liang S,Sun X,et al.Drug resistance and virological failure among HIV-infected patients after a decade of antiretroviral treatment expansion in eight provinces of China[J].PLoS One,2016,11(12):e0166661.
[42] 赵砚,吕娅妮,康续,等.239例治疗失败的HIV感染者HIV-1亚型及耐药分析[J].中国艾滋病性病,2020,26(10):1045-1048.
[43] 杨萱,孙燕,霍玉奇,等.河南省抗病毒治疗失败的艾滋病患者耐药特征[J].中华流行病学杂志,2023,44(11):1795-1801.
[44] Lan Y,Ling X,Deng X,et al.Drug resistance profile among HIV-1 infections experiencing ART with low-level viral load in Guangdong China during 2011-2022:a retrospective study[J].Infect Drug Resist,2023,16:4953-4964.
[45] Yu D,Liang B,Yang Y,et al.Prevalence of drug resistance and genetic transmission networks among human immunodeficiency virus/acquired immunodeficiency syndrome patients with antiretroviral therapy failure in Guangxi,China[J].AIDS Res Hum Retroviruses,2022,38(10):822-830.
[46] 冯玉婷,许玉军,马岳绒,等.海南省抗病毒治疗失败HIV/AIDS患者HIV-1亚型及基因型耐药分析[J].中国热带医学,2021,21(6):594-599.
[47] 柳兴凤,李志坚,方星,等.2013—2017年贵州省HIV/AIDS病人抗病毒治疗后病毒抑制和耐药监测研究[J].中国艾滋病性病,2020,26(1):28-32.
[48] 王凤英,金涛,胡晓远,等.新疆1 816名艾滋病病毒抑制失败患者耐药分析[J].现代预防医学,2018,45(13):2447-2450.
[49] 黄永迪,王凤英,王吉亮,等.新疆维吾尔自治区阿克苏地区艾滋病抗病毒治疗失败人群耐药及分子网络分析 [J].病毒学报,2024,40(4): 862-868.
[50] Yuan D,Liu M,Li Y,et al.Genetic transmission networks of HIV-1 CRF07_BC strain among HIV-1 infections with virologic failure of ART in a minority area of China:a population-based study[J].BMC Infect Dis,2020,20(1):631.
[51] 刘磊,左中宝,廖玲洁,等.中国部分地区HIV抗病毒治疗停药患者的耐药研究[J].热带医学杂志,2018,18(12):1613-1618+1634.
[52] 王继宝,石瑞紫,王译葵,等.德宏傣族景颇族自治州276例抗病毒治疗脱失的HIV感染者的毒株基因亚型和耐药分析[J].中国艾滋病性病,2020,26(8):809-813+856.
[53] Zheng S,Wu J,Hao J,et al.Epidemic characteristics of HIV drug resistance in Hefei,Anhui Province[J].Pathogens,2022,11(8):866.
[54] Cohen MS,Gamble T,McCauley M.Prevention of HIV transmission and the HPTN 052 study[J].Annu Rev Med,2020,71:347-360.
[55] Jia Z,Mao Y,Zhang F,et al.Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003-11):a national observational cohort study[J].Lancet,2013,382(9899):1195-1203.
[56] Liu P,Tang Z,Lan G,et al.Early antiretroviral therapy on reducing HIV transmission in China:strengths,weaknesses and next focus of the program[J].Sci Rep,2018,8(1):3431.
[57] Ma G,Chen H,Chen J,et al.HIV transmission between spouses living in Lu’an city,Anhui province,China:a longitudinal study[J].Epidemiol Infect,2019,147:e205.
[58] Rodger AJ,Cambiano V,Bruun T,et al.Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER):final results of a multicentre,prospective,observational study[J].Lancet,2019,393(10189):2428-2438.
[59] Awad SF,Chemaitelly H,Abu-Raddad LJ.Temporal evolution of HIV sero-discordancy patterns among stable couples in sub-Saharan Africa[J].PLoS One,2018,13(4):e0196613.
[60] Hayes RJ,Donnell D,Floyd S,et al.Effect of universal testing and treatment on HIV incidence - HPTN 071 (PopART)[J].N Engl J Med,2019,381(3):207-218.
[61] Kang R,Li J,Chen H,et al.Using longitudinal genetic-network study to understand HIV treatment-as-prevention[J].AIDS,2021,35(6):947-955.
[62] Chen J,Chen H,Li J,et al.Genetic network analysis of human immunodeficiency virus sexual transmission in rural Southwest China after the expansion of antiretroviral therapy:a population-based study[J].Front Microbiol,2022,13:962477.
[63] Chen Y,Cao Z,Li J,et al.HIV transmission and associated factors under the scale-up of HIV antiretroviral therapy:a population-based longitudinal molecular network study[J].Virol J,2023,20(1):289.
[64] Chamie G,Kamya MR,Petersen ML,et al.Reaching 90-90-90 in rural communities in East Africa: lessons from the Sustainable East Africa Research in Community Health Trial.Curr Opin HIV AIDS,2019,14(6):449-454.
[65] 张娜,范凌云,杨兴光,等.基于风险估计方程探讨 “三个90%” 目标实现对降低山东省HIV新发感染的影响[J].中华流行病学杂志,2020,41(9):1499-1503.
[66] Jin X,Shi L,Wang C,et al.Cost-effectiveness of oral pre-exposure prophylaxis and expanded antiretroviral therapy for preventing HIV infections in the presence of drug resistance among men who have sex with men in China:a mathematical modelling study[J].Lancet Reg Health West Pac,2022,23:100462.
[67] Shen M,Xiao Y,Rong L,et al.The impact of attrition on the transmission of HIV and drug resistance[J].AIDS,2023,37(7):1137-1145.
[68] Lai H,Li R,Li Z,et al.Modelling the impact of treatment adherence on the transmission of HIV drug resistance[J].J Antimicrob Chemother,2023,78(8):1934-1943.